Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice

Neuropharmacology

Volumn 85, Issue , 2014, Pages 314-327

  Imeri, Faik ^a   Fallegger, Daniel ^a   Zivkovic, Aleksandra ^b,e   Schwalm, Stephanie ^b   Enzmann, Gaby ^c   Blankenbach, Kira ^b   Meyer Zu Heringdorf, Dagmar ^b   Homann, Thomas ^d   Kleuser, Burkhard ^d   Pfeilschifter, Josef ^b   Engelhardt, Britta ^c   Stark, Holger ^b,e   Huwiler, Andrea ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF POTSDAM   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Endothelial cells; Fingolimod; Multiple sclerosis; Permeability; Sphingosine 1 phosphate; ST 1071; ST 968

Indexed keywords

7A (4 OCTYLPHENETHYL)TETRAHYDRO 1H OXAZOLO[3,4 C]OXAZOLE; 7A [4 (HEPTYLOXY)PHENETHYL]TETRAHYDRO 1H OXAZOLO[3,4 C]OXAZOLE; CD31 ANTIGEN; FINGOLIMOD; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; OXAZOLE DERIVATIVE; ST 1071; ST 968; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 7A-(4-(HEPTYLOXY)PHENETHYL)TETRAHYDRO-1H-OXAZOLO(3,4-C)OXAZOLE; 7A-(4-OCTYLPHENETHYL)TETRAHYDRO-1H-OXAZOLO(3,4-C)OXAZOLE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MEMBRANE PERMEABILITY; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENDOTHELIUM CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPLEEN CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMAN; LYMPHOCYTE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE; U937 CELL LINE;

ANIMALS; CELL LINE; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CHEMOTAXIS; CHO CELLS; CRICETULUS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; OXAZOLES; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; T-LYMPHOCYTES; U937 CELLS;

EID: 84903199023     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.05.012     Document Type: Article

References (58)

1. el-S. Akool, A. Doller, R. Müller, P. Gutwein, C. Xin, A. Huwiler, J. Pfeilschifter, and W. Eberhardt Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway J. Biol. Chem. 280 2005 39403 39416 (Pubitemid 41713898)
2. S.E. Alvarez, S. Milstien, and S. Spiegel Autocrine and paracrine roles of sphingosine-1-phosphate Trends Endocrinol. Metab. 18 2007 300 307 (Pubitemid 47531961)
3. J.W. Antoon, M.D. White, E.M. Slaughter, J.L. Driver, H.S. Khalili, S. Elliott, C.D. Smith, M.E. Burow, and B.S. Beckman Targeting NFKB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 Cancer Biol. Ther. 11 2011 678 689
4. C. Boz, M. Ozmenoglu, S. Velioglu, K. Kilinc, A. Orem, Z. Alioglu, and V. Altunavoglu Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta Clin. Neurol. Neurosurg. 108 2006 124 128 (Pubitemid 43075529)
5. V. Brinkmann, M.D. Davis, C.E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, C.A. Foster, M. Zollinger, and K.R. Lynch The immune modulator FTY720 targets sphingosine 1-phosphate receptors J. Biol. Chem. 277 2002 21453 21457 (Pubitemid 34952287)
6. V. Brinkmann, J.G. Cyster, and T. Hla FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function Am. J. Transpl. 4 2004 1019 1025 (Pubitemid 38868590)
7. V. Brinkmann Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol. Ther. 115 2007 84 105 (Pubitemid 46990553)
8. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, and P. Burtin Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug. Discov. 9 2010 883 897
9. K. Chiba, Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki, and Y. Hoshino FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing J. Immunol. 160 1998 5037 5044 (Pubitemid 28215340)
10. K. Chiba FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors Pharmacol. Ther. 108 2005 308 319 (Pubitemid 41691870)
11. J. Chun, T. Hla, K.R. Lynch, S. Spiegel, and W.H. Moolenaar International Union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature Pharmacol. Rev. 62 2010 579 587
12. J. Chun, and V. Brinkmann A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discov. Med. 12 2011 213 228
13. J.M. Cook-Mills, and T.L. Deem Active participation of endothelial cells in inflammation J. Leukoc. Biol. 77 2005 487 495 (Pubitemid 40489524)
14. J.G. Cyster Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs Annu. Rev. Immunol. 23 2005 127 159 (Pubitemid 40563167)
15. A. Döring, M. Wild, D. Vestweber, U. Deutsch, and B. Engelhardt E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice J. Immunol. 179 2007 8470 8479
16. B. Dubois, S. Masure, U. Hurtenbach, L. Paemen, H. Heremans, J. van den Oord, R. Sciot, T. Meinhardt, G. Hämmerling, G. Opdenakker, and B. Arnold Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions J. Clin. Invest. 104 1999 1507 1515 (Pubitemid 30002362)
17. S.M. Dudek, S.M. Camp, E.T. Chiang, P.A. Singleton, P.V. Usatyuk, Y. Zhao, V. Natarajan, and J.G. Garcia Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor Cell. Signal. 19 2007 1754 1764 (Pubitemid 46935431)
18. C.J. Edgell, C.C. McDonald, and J.B. Graham Permanent cell line expressing human factor VIII-related antigen established by hybridization Proc. Natl. Acad. Sci. U. S. A 80 1983 3734 3737 (Pubitemid 13063134)
19. D.R. Edwards, K.J. Leco, P.P. Beaudry, P.W. Atadja, C. Veillette, and K.T. Riabowol Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts Exp. Gerontol. 31 1996 207 223 (Pubitemid 26079673)
20. J. Fandrey, A. Huwiler, S. Frede, J. Pfeilschifter, and W. Jelkmann Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression Eur. J. Biochem. 226 1994 335 340 (Pubitemid 24379051)
21. C.A. Foster, D. Mechtcheriakova, M.K. Storch, B. Balatoni, L.M. Howard, F. Bornancin, A. Wlachos, J. Sobanov, A. Kinnunen, and T. Baumruker FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage Brain Pathol. 19 2009 254 266
22. E.J. Goetzl, and M.H. Graler Sphingosine 1-phosphate and its type 1 G protein-coupled receptor: trophic support and functional regulation of T lymphocytes J. Leukoc. Biol. 76 2004 30 35 (Pubitemid 38857168)
23. P.J. Gonzalez-Cabrera, E. Jo, M.G. Sanna, S. Brown, N. Leaf, D. Marsolais, M.T. Schaeffer, J. Chapman, M. Cameron, M. Guerrero, E. Roberts, and H. Rosen Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions Mol. Pharmacol. 74 2008 1308 1318
24. M. Graeler, G. Shankar, and E.J. Goetzl Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate J. Immunol. 169 2002 4084 4087 (Pubitemid 35178174)
25. M.H. Gräler, and E.J. Goetzl The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors FASEB J. 18 2004 551 553
26. D. Graesser, A. Solowiej, M. Bruckner, E. Osterweil, A. Juedes, S. Davis, N.H. Ruddle, B. Engelhardt, and J.A. Madri Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice J. Clin. Invest. 109 2002 383 392 (Pubitemid 34141812)
27. G.L. Harris, M.B. Creason, G.B. Brulte, and D.R. Herr In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody PLoS One 7 2012 e35129
28. A. Huwiler, and J. Pfeilschifter Stimulation by extracellular ATP and UTP of the mitogen-activated protein kinase cascade and proliferation of rat renal mesangial cells Br. J. Pharmacol. 113 1994 1455 1463 (Pubitemid 24364434)
29. A. Huwiler, F. Döll, S. Ren, S. Klawitter, A. Greening, I. Römer, S. Bubnova, L. Reinsberg, and J. Pfeilschifter Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism Biochim. Biophys. Acta. 1761 2006 367 376
30. A. Huwiler, and U. Zangemeister-Wittke Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy Crit. Rev. Oncol. Hematol. 63 2007 150 159 (Pubitemid 46990918)
31. A. Huwiler, and J. Pfeilschifter New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets Biochem. Pharmacol. 75 2008 1893 1900
32. A. Huwiler, and J. Pfeilschifter Lipids as targets for novel anti-inflammatory therapies Pharmacol. Ther. 124 2009 96 112
33. E. Jo, M.G. Sanna, P.J. Gonzalez-Cabrera, S. Thangada, G. Tigyi, D.A. Osborne, T. Hla, A.L. Parrill, and H. Rosen S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate Chem. Biol. 12 2005 703 715 (Pubitemid 43142048)
34. M. Maceyka, K.B. Harikumar, S. Milstien, and S. Spiegel Sphingosine-1-phosphate signaling and its role in disease Trends Cell. Biol. 22 2012 50 60
35. S. Mandala, R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G.J. Shei, D. Card, C. Keohane, M. Rosenbach, J. Hale, C.L. Lynch, K. Rupprecht, W. Parsons, and H. Rosen Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 2002 346 349 (Pubitemid 34303689)
36. M. Matloubian, C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, V. Brinkmann, M.L. Allende, R.L. Proia, and J.G. Cyster Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360 (Pubitemid 38133663)
37. H. Matsuyuki, Y. Maeda, K. Yano, K. Sugahara, K. Chiba, T. Kohno, and Y. Igarashi Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P Cell. Mol. Immunol. 3 2006 429 437
38. M. Mehling, L. Kappos, and T. Derfuss Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions Curr. Neurol. Neurosci. Rep. 11 2011 492 497
39. W.A. Müller Mechanisms of leukocyte transendothelial migration Annu. Rev. Pathol. 6 2011 323 344
40. H.C. Müller, A.C. Hocke, K. Hellwig, B. Gutbier, H. Peters, S.M. Schönrock, T. Tschernig, A. Schmiedl, S. Hippenstiel, P.D. N'Guessan, S. Rosseau, N. Suttorp, and M. Witzenrath The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice Pulm. Pharmacol. Ther. 24 2011 377 385
41. M.L. Oo, S. Thangada, M.T. Wu, C.H. Liu, T.L. Macdonald, K.R. Lynch, C.Y. Lin, and T. Hla Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor J. Biol. Chem. 282 2007 9082 9089 (Pubitemid 47093504)
42. X. Peng, P.M. Hassoun, S. Sammani, B.J. McVerry, M.J. Burne, H. Rabb, D. Pearse, R.M. Tuder, and J.G. Garcia Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury Am. J. Respir. Crit. Care Med. 169 2004 1245 1251 (Pubitemid 38680403)
43. T. Sanchez, T. Estrada-Hernandez, J.H. Paik, M.T. Wu, K. Venkataraman, V. Brinkmann, K. Claffey, and T. Hla Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability J. Biol. Chem. 278 2003 47281 47290 (Pubitemid 37452317)
44. T. Sanchez, and T. Hla Structural and functional characteristics of S1P receptors J. Cell. Biochem. 92 2004 913 922 (Pubitemid 44264241)
45. M. Schuchardt, M. Tölle, J. Prüfer, and M. van der Giet Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system Br. J. Pharmacol. 163 2011 1140 1162
46. S. Schwalm, J. Pfeilschifter, and A. Huwiler Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube Formation Br. J. Pharmacol. 160 2010 1641 1651
47. S.-C. Senksen, C. Bode, and M.H. Graler Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to Prolonged efficacy j Pharmacol. Exp. Ther. 328 2009 963 969
48. S.F. Soriano, M. Hons, K. Schumann, V. Kumar, T.J. Dennier, R. Lyck, M. Sixt, and J.V. Stein In vivo analysis of uropod function during physiological T cell trafficking J. Immunol. 187 2011 2356 2364
49. H. Stark, A. Zivkovic, A. Huwiler, and J. Pfeilschifter Novel Sphingolipid Heterocyclic Compounds as Modulators of Sphingolipid Signalling and Uses Thereof PCT WO 2012131096A1 2012
50. R.J. Stewart, T.S. Kashour, and P.A. Marsden Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells J. Immunol. 156 1996 1221 1228
51. P. Turowski, P. Adamson, and J. Greenwood Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation Cell. Mol. Neurobiol. 25 2005 153 170 (Pubitemid 40558588)
52. L. Wang, E.T. Chiang, J.T. Simmons, J.G. Garcia, and S.M. Dudek FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl Eur. Respir. J. 38 2011 78 88
53. A. Woodfin, M.B. Voisin, and S. Nourshargh PECAM-1: a multi-functional molecule in inflammation and vascular biology Arterioscler Thromb. Vasc. Biol. 27 2007 2514 2523 (Pubitemid 350158900)
54. C. Xin, S. Ren, W. Eberhardt, J. Pfeilschifter, and A. Huwiler The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells Br. J. Pharmacol. 147 2007 164 174 (Pubitemid 43151564)
55. V.W. Yong, R.K. Zabad, S. Agrawal, A. Goncalves Dasilva, and L.M. Metz Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators J. Neurol. Sci. 259 2007 79 84 (Pubitemid 47031205)
56. B. Zemann, B. Kinzel, M. Müller, R. Reuschel, D. Mechtcheriakova, N. Urtz, F. Bornancin, T. Baumruker, and A. Billich Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720 Blood 107 2006 1454 1458 (Pubitemid 43242381)
57. Y. Zhao, I.A. Gorshkova, E. Berdyshev, D. He, P. Fu, W. Ma, Y. Su, P.V. Usatyuk, S. Pendyala, B. Oskouian, J.D. Saba, J.G. Garcia, and V. Natarajan Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression Am. J. Respir. Cell. Mol. Biol. 45 2011 426 435
58. A. Zivkovic, and H. Stark Efficient chromatography-free synthesis of the oxy-analogue of fingolimod Tetrahedron Lett. 51 2010 3769 3771